CPC C07K 16/1003 (2023.08) [A61K 31/13 (2013.01); A61K 31/215 (2013.01); A61K 31/45 (2013.01); A61K 31/4706 (2013.01); A61K 31/4965 (2013.01); A61K 31/675 (2013.01); A61K 31/7052 (2013.01); A61K 31/7068 (2013.01); A61K 31/7088 (2013.01); A61K 39/215 (2013.01); A61K 39/42 (2013.01); A61K 45/06 (2013.01); A61P 31/14 (2018.01); A61K 2039/505 (2013.01); A61K 2039/507 (2013.01); C07K 2317/24 (2013.01); C07K 2317/34 (2013.01); C07K 2317/55 (2013.01); C07K 2317/567 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01); C07K 2319/00 (2013.01)] | 30 Claims |
1. A polypeptide that specifically binds a severe acute respiratory syndrome coronavirus 2 Spike glycoprotein (SARS-CoV-2-Spike) comprising:
a) a heavy chain variable domain (VH) that comprises a heavy chain complementarity-determining region (HCDR) 1 comprising the amino acid sequence of SEQ ID NO:77, a HCDR2 comprising the amino acid sequence of SEQ ID NO:80, and a HCDR3 comprising the amino acid sequence of SEQ ID NO:91; and
b) a light chain variable domain (VL) that comprises a light chain complementarity-determining region (LCDR) 1 comprising the amino acid sequence of SEQ ID NO:133, a LCDR2 comprising the amino acid sequence of SEQ ID NO:141, and a LCDR3 comprising the amino acid sequence of SEQ ID NO:144, wherein the polypeptide is an antibody or an antigen-binding fragment thereof.
|